Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Chimerix appoints Allen Melemed as CMO » 07:02
06/22/20
06/22
07:02
06/22/20
07:02
CMRX

Chimerix

$3.17 /

-0.03 (-0.94%)

, LLY

Eli Lilly

$159.90 /

-1.14 (-0.71%)

Chimerix (CMRX) announced…

Chimerix (CMRX) announced the appointment of Allen Melemed, M.D., M.B.A., as chief medical officer. Melemed joins Chimerix from Eli Lilly and Company (LLY), where he spent more than 20 years dedicated to the clinical development and approval of oncology medicines across a broad range of tumor types including VERZENIO, CYRAMZA, LARTRUVO, ALIMTA and RETEVMO among others.

ShowHide Related Items >><<
LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

CMRX Chimerix
$3.17 /

-0.03 (-0.94%)

CMRX Chimerix
$3.17 /

-0.03 (-0.94%)

05/21/20 JonesTrading
Chimerix initiated with a Buy at JonesTrading
08/01/19 H.C. Wainwright
Chimerix price target raised to $7 from $5 at H.C. Wainwright
07/31/19 H.C. Wainwright
Chimerix's newly acquired AML drug had 'impressive' data, says H.C. Wainwright
LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
06/16/20
Fly Intel: Top five analyst upgrades
06/16/20 Guggenheim
Guggenheim upgrades Eli Lilly to Buy after 'transformational' breast cancer data
06/16/20 Guggenheim
Eli Lilly upgraded to Buy from Neutral at Guggenheim
LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

CMRX Chimerix
$3.17 /

-0.03 (-0.94%)

LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

CMRX Chimerix
$3.17 /

-0.03 (-0.94%)

LLY Eli Lilly
$159.90 /

-1.14 (-0.71%)

Over a month ago
Initiation
Chimerix initiated with a Buy at JonesTrading » 09:20
05/21/20
05/21
09:20
05/21/20
09:20
CMRX

Chimerix

$3.39 /

+0.375 (+12.44%)

JonesTrading analyst…

JonesTrading analyst Soumit Roy initiated coverage of Chimerix with a Buy rating and $10 price target. Chimerix's DSTAT blocks four different pathways to block AML cells from hiding in the bone marrow, modulates immune cells to prevent AML stem cell survival and allow for faster immune cell recovery, which Roy believes is a better approach than peer's E-selectin specific approach. He expects a "constant flow of news" from the company's ongoing COVID-19 trial, potentially positive updates from BARDA meetings and interim Phase 3 data in first-line AML in 2022, Roy added.

ShowHide Related Items >><<
CMRX Chimerix
$3.39 /

+0.375 (+12.44%)

CMRX Chimerix
$3.39 /

+0.375 (+12.44%)

08/01/19 H.C. Wainwright
Chimerix price target raised to $7 from $5 at H.C. Wainwright
07/31/19 H.C. Wainwright
Chimerix's newly acquired AML drug had 'impressive' data, says H.C. Wainwright
CMRX Chimerix
$3.39 /

+0.375 (+12.44%)

CMRX Chimerix
$3.39 /

+0.375 (+12.44%)

On The Fly
Fly Intel: Pre-market Movers » 09:14
04/29/20
04/29
09:14
04/29/20
09:14
GILD

Gilead

$78.71 /

-1.19 (-1.49%)

, CMRX

Chimerix

$1.51 /

-0.02 (-1.31%)

, BA

Boeing

$130.82 /

+2.31 (+1.80%)

, MA

MasterCard

$264.89 /

-0.2 (-0.08%)

, HUM

Humana

$364.43 /

-9.31 (-2.49%)

, EAT

Brinker

$19.12 /

+1.97 (+11.49%)

, DIN

Dine Brands

$37.31 /

+3.69 (+10.98%)

, GOOG

Alphabet

$1,233.18 /

-42.33 (-3.32%)

, GOOGL

Alphabet Class A

$1,231.16 /

-37.64 (-2.97%)

, NOC

Northrop Grumman

$344.94 /

+0.655 (+0.19%)

, GE

General Electric

$6.80 /

+0.375 (+5.84%)

, GD

General Dynamics

$136.24 /

+1.735 (+1.29%)

, HAS

Hasbro

$77.84 /

+1.1 (+1.43%)

, LH

LabCorp

$176.44 /

-2.35 (-1.31%)

, APRN

Blue Apron

$12.68 /

+1.33 (+11.72%)

, F

Ford

$5.38 /

+0.21 (+4.06%)

, PLYA

Playa Hotels & Resorts

$2.44 /

+0.01 (+0.41%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
GILD Gilead
$78.71 /

-1.19 (-1.49%)

04/27/20 RBC Capital
Gilead's China study modestly favorable, but major impact not likely, says RBC
04/27/20 UBS
Gilead downgraded to Neutral from Buy at UBS
04/24/20 Citi
Citi puts 50:50 odds on Gilead's remdesivir being successsful
04/23/20 Piper Sandler
Piper Sandler says no conclusions can be made from leaked Gilead reports
CMRX Chimerix
$1.51 /

-0.02 (-1.31%)

08/01/19 H.C. Wainwright
Chimerix price target raised to $7 from $5 at H.C. Wainwright
07/31/19 H.C. Wainwright
Chimerix's newly acquired AML drug had 'impressive' data, says H.C. Wainwright
BA Boeing
$130.82 /

+2.31 (+1.80%)

04/28/20 Credit Suisse
Embraer downgraded to Underperform from Neutral at Credit Suisse
04/20/20
Fly Intel: Top five analyst downgrades
04/20/20 Citi
Citi downgrades Boeing to Neutral on 'collapsed' aerospace story
04/20/20 Citi
Boeing downgraded to Neutral from Buy at Citi
MA MasterCard
$264.89 /

-0.2 (-0.08%)

04/27/20 Wedbush
MasterCard price target raised to $300 from $250 at Wedbush
04/23/20 Raymond James
MasterCard price target lowered to $288 from $347 at Raymond James
04/22/20 Guggenheim
Guggenheim sees COVID as 'paradigm-changing' for payments, cuts Visa to Neutral
04/16/20
Fly Intel: Top five analyst downgrades
HUM Humana
$364.43 /

-9.31 (-2.49%)

02/20/20 Stephens
Stephens watching near-term MCO stock reactions after Bloomberg's 'rough' debate
02/18/20 Deutsche Bank
Deutsche raises price targets in Managed Care on fading political risks
01/23/20 UBS
Humana price target raised to $406 from $321 at UBS
01/08/20 Credit Suisse
Humana price target raised to $400 from $378 at Credit Suisse
EAT Brinker
$19.12 /

+1.97 (+11.49%)

04/28/20 Loop Capital
Brinker price target lowered to $24 from $54 at Loop Capital
04/27/20 OTR Global
Brinker downgraded to Mixed from Positive at OTR Global
04/27/20 Wells Fargo
Brinker price target lowered to $17 from $48 at Wells Fargo
04/23/20
Fly Intel: Top five analyst upgrades
DIN Dine Brands
$37.31 /

+3.69 (+10.98%)

04/20/20 Wedbush
Dine Brands price target lowered to $50 from $110 at Wedbush
02/25/20 MKM Partners
Dine Brands downgraded to Neutral from Buy at MKM Partners
02/25/20 Raymond James
Dine Brands approaching fair value after recent gains, says Raymond James
02/25/20 Wedbush
Dine Brands price target raised to $110 from $100 at Wedbush
GOOG Alphabet
$1,233.18 /

-42.33 (-3.32%)

04/29/20 Susquehanna
Alphabet price target raised to $1800 from $1550 at Susquehanna
04/29/20 Oppenheimer
Oppenheimer remains bullish on Alphabet after quarterly results
04/29/20 Stifel
Alphabet price target raised to $1,400 from $1,300 at Stifel
04/29/20 Cowen
Alphabet price target raised to $1525 from $1450 at Cowen
GOOGL Alphabet Class A
$1,231.16 /

-37.64 (-2.97%)

04/29/20 SunTrust
Alphabet price target raised to $1550 from $1350 at SunTrust
NOC Northrop Grumman
$344.94 /

+0.655 (+0.19%)

03/30/20 Bernstein
Northrop Grumman upgraded to Outperform with $386 price target at Bernstein
03/30/20 Bernstein
Northrop Grumman upgraded to Outperform from Market Perform at Bernstein
03/11/20 Goldman Sachs
Goldman cuts targets across Aerospace coverage for COVID-19 impact
02/03/20
Fly Intel: Top five analyst downgrades
GE General Electric
$6.80 /

+0.375 (+5.84%)

04/23/20 Citi
General Electric price target lowered to $9 from $11 at Citi
04/14/20 JPMorgan
General Electric remains 'most expensive value trap ever,' says JPMorgan
03/31/20 JPMorgan
Rockwell, GE least favored Multi-Industry names at JPMorgan
03/27/20 Gabelli
GE CEO 'taking the right steps' in face of 'steeper hill to climb,' says Gabelli
GD General Dynamics
$136.24 /

+1.735 (+1.29%)

04/20/20 Citi
Textron downgraded to Neutral from Buy at Citi
04/20/20 Citi
General Dynamics upgraded to Buy from Neutral at Citi
02/27/20 Susquehanna
General Dynamics free cash flow compelling, Susquehanna upgrades
HAS Hasbro
$77.84 /

+1.1 (+1.43%)

04/27/20 JPMorgan
Hasbro risk/reward 'skewed to the downside,' says JPMorgan
04/21/20 Goldman Sachs
Hasbro price target lowered to $88 from $103 at Goldman Sachs
04/17/20 Wolfe Research
Hasbro initiated with an Outperform at Wolfe Research
04/17/20 Wells Fargo
Hasbro price target lowered to $76 from $105 at Wells Fargo
LH LabCorp
$176.44 /

-2.35 (-1.31%)

04/27/20
Fly Intel: Top five analyst upgrades
04/27/20 Wolfe Research
LabCorp upgraded to Peer Perform from Underperform at Wolfe Research
04/27/20 Citi
LabCorp upgraded to Buy from Neutral at Citi
04/27/20 Citi
Quest Diagnostics upgraded to Buy from Neutral at Citi
APRN Blue Apron
$12.68 /

+1.33 (+11.72%)

02/20/20 SunTrust
Blue Apron price target lowered to $5 from $8 at SunTrust
02/19/20 Canaccord
Blue Apron price target lowered to $5 from $7 at Canaccord
02/19/20 SunTrust
SunTrust cuts Blue Apron target to $5, views sale as likely review outcome
10/31/19 SunTrust
Blue Apron price target cut to $8 from $10 at SunTrust
F Ford
$5.38 /

+0.21 (+4.06%)

04/29/20 Jefferies
Ford should have reached 'peak cash pain' in April, says Jefferies
04/22/20 Morgan Stanley
Morgan Stanley expects Ford to retain full ownership of Ford Credit
04/15/20
Fly Intel: Top five analyst initiations
04/14/20 Goldman Sachs
Ford, GM started at Neutral at Goldman Sachs on anticipated cash burn
PLYA Playa Hotels & Resorts
$2.44 /

+0.01 (+0.41%)

04/29/20 SunTrust
Playa Hotels & Resorts downgraded to Hold from Buy at SunTrust
04/29/20 SunTrust
Playa Hotels & Resorts downgraded to Hold from Buy at SunTrust
04/07/20 Citi
Playa Hotels & Resorts downgraded to Sell from Neutral at Citi
04/03/20 Deutsche Bank
Playa Hotels & Resorts price target lowered to $7 from $11 at Deutsche Bank
Hot Stocks
Chimerix receives FDA clearance for brincidofovir NDA » 08:35
04/29/20
04/29
08:35
04/29/20
08:35
CMRX

Chimerix

$1.51 /

-0.02 (-1.31%)

Chimerix announced that…

Chimerix announced that the company has received clearance from the FDA for a rolling submission of its new drug application, or NDA, for the approval of brincidofovir, or BCV, as a medical countermeasure for smallpox. The company intends to begin the rolling NDA submission for BCV in May with completion targeted for mid-2020. Chimerix is developing BCV as a potential medical countermeasure for smallpox under an ongoing collaboration and funding provided by the Biomedical Advanced Research and Development Authority, or BARDA, part of the office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, under an ongoing USG contract.

ShowHide Related Items >><<
CMRX Chimerix
$1.51 /

-0.02 (-1.31%)

08/01/19 H.C. Wainwright
Chimerix price target raised to $7 from $5 at H.C. Wainwright
07/31/19 H.C. Wainwright
Chimerix's newly acquired AML drug had 'impressive' data, says H.C. Wainwright
Hot Stocks
Chimerix initiates Phase 2/3 trial of DSTAT in acute lung injury » 07:20
04/29/20
04/29
07:20
04/29/20
07:20
CMRX

Chimerix

$1.51 /

-0.02 (-1.31%)

Chimerix announced the…

Chimerix announced the Company's initiation of a Phase 2/3 study of dociparstat sodium in COVID-19 patients with acute lung injury. DSTAT is a glycosaminoglycan derivative of heparin with robust anti-inflammatory properties, including the potential to address underlying causes of coagulation disorders with substantially reduced risk of bleeding complications compared to commercially available forms of heparin.

ShowHide Related Items >><<
CMRX Chimerix
$1.51 /

-0.02 (-1.31%)

08/01/19 H.C. Wainwright
Chimerix price target raised to $7 from $5 at H.C. Wainwright
07/31/19 H.C. Wainwright
Chimerix's newly acquired AML drug had 'impressive' data, says H.C. Wainwright
Over a quarter ago
Hot Stocks
Chimerix expects to submit BCV NDA for smallpox in mid-2020 » 07:19
02/25/20
02/25
07:19
02/25/20
07:19
CMRX

Chimerix

$1.75 /

+0.025 (+1.45%)

In January, Chimerix…

In January, Chimerix presented data in support of BCV as a potential treatment for smallpox at the 2020 American Society for Microbiology Biothreats Meeting in Arlington, Virginia. The presentation highlighted independent experiments performed in two lethal animal models of smallpox. In these studies, either rabbits or mice were inoculated with rabbitpox or ectromelia virus, respectively, to determine the survival benefit conferred by BCV treatment in animals acutely infected with these orthopoxviruses. Animals were randomized to receive either placebo or BCV at varying time intervals post infection. In both studies, animals that received BCV, even when administered late post-infection, demonstrated a statistically significant survival advantage relative to placebo. Data from these studies are intended to address the requirement under the FDA Animal Efficacy Rule for two different animal models of efficacy. Chimerix is collaborating with the Biomedical Advanced Research and Development Authority for the development of BCV as a potential medical countermeasure for smallpox. This rule allows for testing the efficacy of investigational drugs in animal models for diseases which cannot be evaluated in human clinical studies. In cooperation with BARDA, Chimerix has scheduled a pre-NDA meeting with FDA to review the final efficacy and safety data in preparation to submit an NDA. Pending the outcome of this meeting, Chimerix intends to submit a BCV NDA for smallpox in mid-2020. The Company's operating and manufacturing plan assumes entering into a procurement contract with BARDA in 2020 and preparation for delivery of BCV into the Strategic National Stockpile in 2021.

ShowHide Related Items >><<
CMRX Chimerix
$1.75 /

+0.025 (+1.45%)

08/01/19 H.C. Wainwright
Chimerix price target raised to $7 from $5 at H.C. Wainwright
07/31/19 H.C. Wainwright
Chimerix's newly acquired AML drug had 'impressive' data, says H.C. Wainwright
03/05/19 H.C. Wainwright
Chimerix price target lowered to $7 from $10 at H.C. Wainwright
Hot Stocks
Chimerix to initiate Phase 3 trial of DSTAT w/ chemotherapy mid-year » 07:18
02/25/20
02/25
07:18
02/25/20
07:18
CMRX

Chimerix

$1.75 /

+0.025 (+1.45%)

Chimerix recently…

Chimerix recently conducted an end of Phase 2 meeting with the U.S. Food and Drug Administration related to the Company's development of DSTAT in AML. Following that meeting, Chimerix incorporated FDA's feedback on key elements of the Phase 3 clinical trial and has since submitted a full protocol for final FDA review. Chimerix plans to initiate a Phase 3 trial mid-year of DSTAT in combination with standard chemotherapy in newly diagnosed AML patients. The proposed Phase 3 trial will be a randomized, double-blind trial of approximately 570 newly diagnosed AML patients. The trial will include patients 60 years of age or older who have an intermediate or adverse genetic risk profile. It will also include patients between 18 and 60 years of age who have an adverse genetic risk profile. Patients will be randomized 1:1 to receive DSTAT in combination with standard of care cytarabine plus anthracycline induction and cytarabine consolidation chemotherapy or to receive standard of care induction and consolidation chemotherapy alone. Patients with FLT-3 mutations will be allowed in the study and will be eligible to receive midostaurin. The primary endpoint of the proposed trial will be overall survival. In addition, FDA has indicated that event-free survival, using complete response with hematologic recovery to define induction success, is acceptable as an endpoint for regulatory approval. Other endpoints to be evaluated in the proposed trial include minimal residual disease, relapse-free survival, time to hematologic recovery, and induction response. In order to supplement the previously reported data from the pilot and Phase 2 trials and provide additional evidence of DSTAT's mechanism of action, the proposed Phase 3 trial includes an early assessment of comparative CR and MRD rates among the first 80 evaluable patients. This data is expected to be unblinded, reported publicly, and available for ongoing analysis of later endpoints. Prior to potential unblinding, this data will be reviewed by an independent Data Monitoring Committee. The DMC will have the discretion to maintain blinding of the data from this early assessment in the event the DSTAT arm shows exceptional advantages to the control arm on CR and/or MRD, at certain pre-specified thresholds, which would allow inclusion of these patients in the final analysis. The Company expects to incur approximately $15M in clinical trial expenses up to and including this early assessment.

ShowHide Related Items >><<
CMRX Chimerix
$1.75 /

+0.025 (+1.45%)

08/01/19 H.C. Wainwright
Chimerix price target raised to $7 from $5 at H.C. Wainwright
07/31/19 H.C. Wainwright
Chimerix's newly acquired AML drug had 'impressive' data, says H.C. Wainwright
03/05/19 H.C. Wainwright
Chimerix price target lowered to $7 from $10 at H.C. Wainwright
Earnings
Chimerix reports Q4 EPS (6c), two est. (17c) » 07:16
02/25/20
02/25
07:16
02/25/20
07:16
CMRX

Chimerix

$1.75 /

+0.025 (+1.45%)

Reports Q4 revenue $6.8M,…

Reports Q4 revenue $6.8M, two est. $750,000. "The transformation and progress we made in 2019 has laid the foundation for Chimerix to achieve a number of value-creating milestones in 2020," said Mike Sherman, Chief Executive Officer of Chimerix. "The team has continued to execute extremely well as we plan to file our first New Drug Application for brincidofovir as a medical countermeasure for smallpox and advance our promising dociparstat sodium program into pivotal Phase 3 clinical development as a front-line treatment for acute myeloid leukemia."

ShowHide Related Items >><<
CMRX Chimerix
$1.75 /

+0.025 (+1.45%)

08/01/19 H.C. Wainwright
Chimerix price target raised to $7 from $5 at H.C. Wainwright
07/31/19 H.C. Wainwright
Chimerix's newly acquired AML drug had 'impressive' data, says H.C. Wainwright
03/05/19 H.C. Wainwright
Chimerix price target lowered to $7 from $10 at H.C. Wainwright
Hot Stocks
Chimerix appoints Pratik Multani to board of directors » 08:19
02/24/20
02/24
08:19
02/24/20
08:19
CMRX

Chimerix

$1.72 /

-0.015 (-0.86%)

Chimerixannounced the…

Chimerixannounced the appointment of Pratik S. Multani, M.D., to its Board of Directors, effective immediately. Dr. Multani currently serves as Chief Medical Officer of ORIC Pharmaceuticals. He replaces Jim Daly, who recently stepped down from the Board of Directors.

ShowHide Related Items >><<
CMRX Chimerix
$1.72 /

-0.015 (-0.86%)

08/01/19 H.C. Wainwright
Chimerix price target raised to $7 from $5 at H.C. Wainwright
07/31/19 H.C. Wainwright
Chimerix's newly acquired AML drug had 'impressive' data, says H.C. Wainwright
03/05/19 H.C. Wainwright
Chimerix price target lowered to $7 from $10 at H.C. Wainwright
Hot Stocks
Chimerix presents data supporting brincidofovir as potential smallpox treatment » 08:02
01/29/20
01/29
08:02
01/29/20
08:02
CMRX

Chimerix

$1.81 /

-0.035 (-1.90%)

Chimerix announces that…

Chimerix announces that data in support of brincidofovir as a potential treatment for smallpox were highlighted in an oral presentation and poster at the 2020 American Society for Microbiology Biothreats Meeting taking place January 28-30, 2020 in Arlington, Virginia. Chimerix is developing BCV as a medical countermeasure against smallpox. The poster titled, "Brincidofovir Treatment Efficacy in Two Well Characterized Orthopoxvirus Infection Models of Smallpox," can be accessed on the Investor page of the Chimerix corporate website. Independent experiments were performed in two lethal animal models of smallpox. In these studies, either rabbits or mice were inoculated with rabbitpox or ectromelia virus, respectively, to determine the survival benefit of BCV in animals acutely infected with these orthopoxviruses. These animal models are being studied in connection with the FDA Animal Rule to determine the utility of BCV as a medical countermeasure against the human orthopoxvirus disease, smallpox. Animals were randomized to receive either placebo or BCV treatment at varying intervals post infection. In both studies, animals that received BCV, regardless of time post-infection, demonstrated a statistically significant survival advantage relative to placebo.

ShowHide Related Items >><<
CMRX Chimerix
$1.81 /

-0.035 (-1.90%)

08/01/19 H.C. Wainwright
Chimerix price target raised to $7 from $5 at H.C. Wainwright
07/31/19 H.C. Wainwright
Chimerix's newly acquired AML drug had 'impressive' data, says H.C. Wainwright
03/05/19 H.C. Wainwright
Chimerix price target lowered to $7 from $10 at H.C. Wainwright
02/06/19 H.C. Wainwright
Chimerix 'in good hands' while CEO replacement is sought, says H.C. Wainwright

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.